Detalles de la búsqueda
1.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler;
26(13): 1719-1728, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31675266
2.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler;
26(1): 48-56, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785358
3.
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
Mult Scler;
24(4): 535-539, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28304217
4.
Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy.
Eur J Health Econ;
24(7): 1061-1072, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36260149
5.
A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis.
Diabetes Metab Syndr;
15(6): 102328, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34752935
6.
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial.
ACR Open Rheumatol;
2(11): 672-680, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33164349
7.
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
Arthritis Res Ther;
22(1): 206, 2020 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32907617
8.
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
Mult Scler J Exp Transl Clin;
6(4): 2055217320972137, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33414927
9.
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
J Allergy Clin Immunol Pract;
8(2): 516-526, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31521831
10.
Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
J Clin Neurosci;
59: 229-231, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30348586
11.
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
RMD Open;
5(2): e001017, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31673415
12.
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
J Comp Eff Res;
8(5): 305-316, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30754997
13.
Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.
Mult Scler J Exp Transl Clin;
4(2): 2055217318775236, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29796289
14.
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Mult Scler Relat Disord;
26: 211-218, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30273841
15.
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.
Neurol Neuroimmunol Neuroinflamm;
4(5): e379, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28680917
16.
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.
Neurol Neuroimmunol Neuroinflamm;
4(5): e390, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28828394
17.
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Neurology;
89(11): 1107-1116, 2017 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28835401
18.
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Neurology;
89(11): 1117-1126, 2017 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28835403
19.
Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor.
Clin Cancer Res;
11(12): 4382-7, 2005 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15958621
20.
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Mult Scler Relat Disord;
10: 204-212, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27919491